Murakawa Yasuko
Dept. of Cancer Chemotherapy, Miyagi Cancer Center, Japan.
Gan To Kagaku Ryoho. 2013 Jun;40(6):693-6.
Chemotherapy-induced febrile neutropenia(FN)is a major risk factor for severe infections, with a dose-limiting toxicity that necessitates dose reductions and/or delays in scheduled chemotherapy sessions. Therefore, the use of granulocyte colony- stimulating factors(G-CSF)is recommended in cancer patients at a risk of chemotherapy-induced FN. Three types of GCSF, filgrastim, lenograstim, and nartograstim, have been available thus far. The differences in potency and efficacy among these G-CSF needs to be thoroughly understood. Prophylactic G-CSF is recommended in patients receiving a chemotherapy regimen associated with a high risk(>20%)of FN. A chemotherapy regimen associated with intermediate risk(10-20%)of FN, requires particular attention to the neutrophil count and observation of symptoms of infection after chemotherapy. Prophylactic G-CSF could be included in subsequent chemotherapy regimens, if needed.
化疗引起的发热性中性粒细胞减少症（FN）是严重感染的主要危险因素，其剂量限制性毒性使得化疗疗程必须减少剂量和/或推迟。因此，对于有化疗引起FN风险的癌症患者，建议使用粒细胞集落刺激因子（G-CSF）。迄今为止，有三种类型的G-CSF，即非格司亭、来格司亭和那托司亭。需要深入了解这些G-CSF在效力和疗效方面的差异。对于接受FN高风险（>20%）化疗方案的患者，建议预防性使用G-CSF。与FN中度风险（10-20%）相关的化疗方案，需要特别关注中性粒细胞计数以及化疗后感染症状的观察。如有需要，后续化疗方案中可加入预防性G-CSF。
